Enliven Therapeutics (ELVN) to Release Quarterly Earnings on Tuesday

Key Points

• Enliven Therapeutics is set to release its Q2 2025 earnings on August 12th, with analysts forecasting earnings of ($0.54) per share for the quarter.
• The company's stock recently traded at $18.96, with a market cap of $930.12 million, and insider transactions showed significant selling activity by executives.
• Brokerages have varying price targets for Enliven Therapeutics, with reports indicating an average target of $41.20 and several analysts rating the stock as a "buy".

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Enliven Therapeutics to post earnings of ($0.54) per share for the quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded up $0.22 on Tuesday, hitting $18.96. 47,935 shares of the company's stock were exchanged, compared to its average volume of 365,694. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.03. The firm has a 50-day moving average price of $20.68 and a 200-day moving average price of $20.09. The company has a market cap of $930.12 million, a P/E ratio of -9.87 and a beta of 0.93.

Insider Transactions at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 3,250 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $20.46, for a total transaction of $66,495.00. Following the sale, the chief financial officer directly owned 23,000 shares of the company's stock, valued at $470,580. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $22.29, for a total value of $278,625.00. Following the transaction, the insider directly owned 952,688 shares in the company, valued at $21,235,415.52. The trade was a 1.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 105,751 shares of company stock valued at $2,169,325 over the last 90 days. Insiders own 25.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Enliven Therapeutics during the first quarter worth about $578,000. Goldman Sachs Group Inc. increased its position in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock worth $4,167,000 after buying an additional 80,506 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock valued at $428,000 after purchasing an additional 1,693 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on ELVN. Robert W. Baird upped their price objective on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. The Goldman Sachs Group initiated coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Finally, Jones Trading reduced their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.